Page 27 - Chumakov News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Only some categories of residents need to maintain high antibodies against COVID — expert One’s habits, age, and the presence of concomitant diseases should be taken into account when answering the question of whether the constantly high antibody titer is needed MOSCOW, May 27. /TASS/. Only those with high social activity as well as the staff of the "red zones" in medical institutions have to maintain a high level of antibodies against the coronavirus infection, Director General of the Chumakov Federal Scientific Center Aydar Ishmukhametov reported at the 9th international congress ...

Теперь о ходе массовой вакцинации от коронавируса. Первую партию препарата «КовиВак», это разработка центра имени Чумакова, доставили в Кабардино-Балкарию.

Вакцины против COVID-19, вероятно, придется обновлять, и прививать ими население ежегодно, достаточное количество данных по эффективности существующих вакцин... РИА Новости, 27.05.2021

Russian manufacturers can ensure sufficient supply of COVID-19 vaccines - ministry According to the Russian First Deputy Industry and Trade Minister Vasily Osmakov, no problems with delivering the vaccines to Russian regions have been reported so far MOSCOW, May 26. /TASS/. Manufacturers of anti-coronavirus vaccines in Russia can ensure sufficient supply of them even if demand grows, Russian First Deputy Industry and Trade Minister Vasily Osmakov said. "This information is restricted to a certain extent, so my answer will be short: yes, we can," he said. "Manufacturing facilities work in acco...

25 May 2021 13:30 Russia's Chumakov Center plans to start Phase 3 trials of CoviVac vaccine in several weeks - general director MOSCOW. May 25 (Interfax) - Phase 3 clinical trials of the Covid-19 whole-virion vaccine CoviVac may begin in a couple of weeks, according to Aidar Ishmukhametov, general director of the Russian Academy of Sciences' Chumakov Federal Center for Research and Development of Immune-and-Biological Products, the vaccine's developer. "It is up to the Health Ministry to make this decision. We submitted [documents to start Phase 3 trials of the CoviVac vaccine], we were a...